Table 1 Baseline characteristics of the study cases at enrollment from the different sites
Year | Drug/site | Enrolled numbers | Age (years) Median (range) | Sex (male) n (%) | Temperature (°C) Mean (SD) | Parasitaemia (μl) GM (range) |
|---|---|---|---|---|---|---|
2011 | ASAQ | |||||
 Ujiji | 73 | 2.7 (0.2–5) | 37 (50.7) | 38.4 (1.3) | 48,183 (1600–198,194) | |
 Kibaha | 29 | 3.0 (1–5) | 17 (58.6) | 38.2 (1.1) | 6162 (1034–80,000) | |
AL | ||||||
 Muheza | 32 | 2.0 (1–5) | 18 (56.3) | 37.9 (1.2) | 24,400 (1680–160,457) | |
2012 | AL | |||||
 Chamwino | 26 | 5.0 (1–8) | 13 (50.0) | 38.1 (1) | 8146 (1120–36,800) | |
 Kyela | 44 | 3.0 (1–10) | 20 (45.5) | 38.1 (1.2) | 32,741 (1680–180,800) | |
 Nagaga | 62 | 3.0 (1–10) | 30 (48.4) | 38.3 (0.9) | 22,368 (1040–149,382) | |
2015 | AL | |||||
 Kyela | 80 | 6.5 (0.6–60) | 40 (50.0) | 38.1 (1.3) | 13,303 (640–84,480) | |
DHA-PQ | ||||||
 Rufiji | 82 | 10 (0.8–87) | 44 (51.2) | 37.6 (0.9) | 12,007 (960–199,120) | |